Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Crohn's disease
Biotech
Ventyx's last hope for inflammatory med ends in Crohn's failure
Ventyx’s Crohn’s drug didn't help patients achieve remission in a phase 2 trial, sending the biotech’s shares down 20% pre-market Monday morning.
Annalee Armstrong
Jul 29, 2024 9:45am
Lilly inks $3.2B Morphic buyout to take on Takeda in IBD
Jul 8, 2024 8:20am
AbbVie pays $150M for preclinical IBD drug to join TL1A race
Jun 13, 2024 9:45am
Agomab uses $100M series C to push Crohn's drug through phase 2
Oct 11, 2023 8:50am
Sanofi pays Teva $500M to join red-hot bowel disease race
Oct 4, 2023 6:00am
AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral
Jun 1, 2023 6:10am
